Orphan Drug Designation
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
Orphan Drug Designation is a status FDA grants to a drug intended to treat a rare disease or condition — in the US, generally affecting fewer than 200,000 people — providing incentives including tax credits for clinical trial costs, exemption from certain user fees, and seven years of market exclusivity upon approval, independent of any patent protection.
Designation is granted based on the rare-disease prevalence criterion, or, rarely, on a showing that the sponsor cannot recover development costs from US sales, and is distinct from and does not guarantee approval — a designated drug still must clear the full safety and efficacy review for its intended indication.
The EU runs a parallel but separately administered orphan medicinal product designation, evaluated by EMA’s Committee for Orphan Medicinal Products against its own prevalence threshold — no more than 5 in 10,000 persons in the EU — and significant-benefit criteria, carrying up to ten years of EU market exclusivity; a sponsor pursuing both markets applies to each regulator separately.
- —Granted for drugs treating rare diseases — US threshold generally under 200,000 patients affected
- —Provides tax credits, user fee exemptions, and 7 years of US market exclusivity
- —Designation does not exempt the drug from the standard safety/efficacy review
- —EU orphan designation is separately administered by EMA’s COMP with its own prevalence threshold
Orphan Drug Act of 1983; 21 CFR Part 316; EU Regulation (EC) No 141/2000 (orphan medicinal products)
Frequently asked questions
What is Orphan Drug Designation?
Orphan Drug Designation is a status FDA grants to a drug intended to treat a rare disease or condition — in the US, generally affecting fewer than 200,000 people — providing incentives including tax credits for clinical trial costs, exemption from certain user fees, and seven years of market exclusivity upon approval, independent of any patent protection.
Which regulations cover Orphan Drug Designation?
Orphan Drug Act of 1983; 21 CFR Part 316; EU Regulation (EC) No 141/2000 (orphan medicinal products)